ライフサイエンスコーパス: cytoreductive surgery

1 e either neoadjuvant chemotherapy or primary cytoreductive surgery.

2 18)F-FES PET/CT was performed shortly before cytoreductive surgery.

3 and hemodynamic findings when injected after cytoreductive surgery.

4 e a week either during tumor growth or after cytoreductive surgery.

5 n with carboplatin and taxane regimens after cytoreductive surgery.

6 apy regimens with or without prior secondary cytoreductive surgery.

7 Survival based on the number of cytoreductive surgeries and the free interval between th

8 fied by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery te

9 inical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Can

10 e demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic rou

11 A large proportion of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal c

12 Patients with PM from CRC admitted for cytoreductive surgery and hyperthermic intraperitoneal c

13 Cytoreductive surgery and hyperthermic intraperitoneal c

14 Therefore, investigators have applied cytoreductive surgery and hyperthermic perioperative che

15 impact on progression-free survival (PFS) of cytoreductive surgery and international variations in su

16 All patients with colorectal PC referred for cytoreductive surgery and intraperitoneal chemotherapy (

17 ere managed by a treatment regimen that used cytoreductive surgery and intraperitoneal chemotherapy.

18 with PC and synchronous LM who had undergone cytoreductive surgery and LM resection followed by intra

19 with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in

20 The therapeutic value of cytoreductive surgery and radiation therapy for posterio

21 l carcinomatosis (PC) who underwent complete cytoreductive surgery and resection of LM, followed by i

22 Women who are fit for primary cytoreductive surgery, and with potentially resectable d

23 atients with advanced-stage disease, maximum cytoreductive surgery appears to be beneficial.

24 The survival benefits of cytoreductive surgery are also applicable to women with

25 years) with abdominopelvic CT before primary cytoreductive surgery available through the Cancer Imagi

26 arian cancer who underwent CT before primary cytoreductive surgery between 1997 and 2004 (mean age, 6

27 PURPOSE OF REVIEW: Cytoreductive surgery combined with hyperthermic intrape

28 The efficacy of cytoreductive surgery combined with perioperative intrap

29 The current evidence suggests that cytoreductive surgery combined with perioperative intrap

30 valuate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperito

31 cer may be treated with a curative intent by cytoreductive surgery (CRS) and hyperthermic intraperito

32 Cytoreductive surgery (CRS) and hyperthermic intraperito

33 zed trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemothe

34 ould impact the failure-to-rescue rate after cytoreductive surgery (CRS) for peritoneal carcinomatosi

35 Cytoreductive surgery (CRS) with hyperthermic intraperit

36 he expansion of treatment options, including cytoreductive surgery followed by chemotherapy with hype

37 gical malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment.

38 e was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of c

39 fic immunotherapy should be considered after cytoreductive surgery for advanced melanoma.

40 Interval cytoreductive surgery has been shown to confer a surviva

41 mic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selecte

42 perthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS).

43 e availability of retroperitoneal staging or cytoreductive surgery if necessary.

44 ospective study of CT images obtained before cytoreductive surgery in 46 women with HGSOC, whose tumo

45 A new treatment strategy starts with cytoreductive surgery in an attempt to remove all visibl

46 Despite continuing debates around cytoreductive surgery in malignant gliomas, there is bro

47 troy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal c

48 However, primary cytoreductive surgery is preferred if there is a high li

49 As such, extensive cytoreductive surgery is required prior to IPC.

50 in metastatic melanoma tumors obtained from cytoreductive surgery of AJCC stage IV melanoma patients

51 r; however, a subset of patients who undergo cytoreductive surgery of distant metastases survive for

52 rent disease may be eligible for a secondary cytoreductive surgery or may require a surgical interven

53 sex (P < .001), age </= 65 years (P = .005), cytoreductive surgery (P < .001), and epithelioid histol

54 ostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with

55 mains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy

56 nt chemotherapy (NACT) compared with primary cytoreductive surgery (PCS).

57 ecurrence develops are candidates for repeat cytoreductive surgery plus intraperitoneal chemotherapy

58 The impact on survival of secondary cytoreductive surgery requires more investigation.

59 he roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and pal

60 We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on p

61 red to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with

62 Primary cytoreductive surgery was associated with improved survi

63 h advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the

64 Histology, grade, stage, and success of cytoreductive surgery were similar for hereditary and sp

65 apy alone has recently been demonstrated for cytoreductive surgery when combined with intraoperative

66 Cytoreductive surgery with hyperthermic intraperitoneal